|
gptkbp:instanceOf
|
gptkb:antibiotic
fluoroquinolone
|
|
gptkbp:approvalYear
|
1987
|
|
gptkbp:ATCCode
|
J01MA02
|
|
gptkbp:bioavailability
|
70% (oral)
|
|
gptkbp:brand
|
gptkb:Proquin_XR
gptkb:Cipro
gptkb:Ciloxan
|
|
gptkbp:CASNumber
|
85721-33-1
|
|
gptkbp:chemicalFormula
|
fluoroquinolone core
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
hypersensitivity to quinolones
|
|
gptkbp:discoveredBy
|
gptkb:Bayer_AG
|
|
gptkbp:drugClass
|
fluoroquinolone antibiotic
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H18FN3O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ciprofloxacin
|
|
gptkbp:KEGGID
|
D00298
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA gyrase
inhibits topoisomerase IV
|
|
gptkbp:MedlinePlusID
|
a601006
a688016
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentedYear
|
1983
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
20–40%
|
|
gptkbp:PubChem_CID
|
2764
CHEMBL8
DB00537
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
ophthalmic
otic
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
QT prolongation
tendon rupture
|
|
gptkbp:synonym
|
gptkb:Ciproxin
Bay o 9867
|
|
gptkbp:UNII
|
5E8K9I0O4U
|
|
gptkbp:usedFor
|
skin infections
urinary tract infections
bacterial infections
gastrointestinal infections
respiratory tract infections
anthrax exposure
bone and joint infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Antibiotics
|
|
gptkbp:bfsLayer
|
4
|